Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Present

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Gastroenterology|February 1, 1973
Imparied lymphocyte responsiveness in inflammatory bowel diseaseD B Sachar, R N Taub, S M Brown, et al.
Gastroenterology|December 2, 1999
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polypsP H Rubin, S Friedman, N Harpaz, et al.
Journal of Clinical Gastroenterology|August 1, 1990
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomenA A Kornbluth, P Salomon, D B Sachar, et al.
The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.
Gastroenterology|September 29, 1999
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseP Rutgeerts, G D'Haens, S Targan, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.
The New England Journal of Medicine|May 6, 1999
Infliximab for the treatment of fistulas in patients with Crohn's diseaseD H Present, P Rutgeerts, S Targan, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Gastroenterology|February 1, 1973
Imparied lymphocyte responsiveness in inflammatory bowel diseaseD B Sachar, R N Taub, S M Brown, et al.
Gastroenterology|December 2, 1999
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polypsP H Rubin, S Friedman, N Harpaz, et al.
Journal of Clinical Gastroenterology|August 1, 1990
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomenA A Kornbluth, P Salomon, D B Sachar, et al.
The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.
Gastroenterology|September 29, 1999
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseP Rutgeerts, G D'Haens, S Targan, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.
The New England Journal of Medicine|May 6, 1999
Infliximab for the treatment of fistulas in patients with Crohn's diseaseD H Present, P Rutgeerts, S Targan, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Pageof 8